Health Management and Economics Research Center, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
BMC Res Notes. 2024 Sep 17;17(1):268. doi: 10.1186/s13104-024-06913-6.
This study aims to assess the economic burden of prostate cancer in Iran by analyzing direct medical costs, direct non-medical costs, and indirect costs. We conducted a cross-sectional cost-of-illness study in Khorramabad, located in western Iran, during 2023, using a prevalence-based, bottom-up approach. Data were collected from 285 prostate cancer patients using questionnaires, interviews, and patient records.
Our study estimated the economic burden of prostate cancer at $744,990. Direct medical costs accounted for 63.50% of this, totaling $153,330, with therapy being the largest component. Direct non-medical costs were $62,130, and indirect costs from productivity losses were $209,760. The calculated overall cost per patient was $2,614.88. Extrapolating from the 2021 Global Burden of Disease data, which reported approximately 83,000 prostate cancer patients in Iran, the national economic burden is estimated at $217,034,040. This substantial burden highlights the need for improved insurance coverage and early detection. The findings suggest that policymakers and healthcare providers in Iran should develop standardized cost analysis methods and enhance financial protection to alleviate economic strain and improve healthcare outcomes and sustainability.
本研究旨在通过分析直接医疗成本、直接非医疗成本和间接成本来评估伊朗前列腺癌的经济负担。我们于 2023 年在伊朗西部的霍拉马巴德进行了一项基于患病率的横断面成本效益研究，采用自下而上的方法。使用问卷、访谈和患者记录从 285 名前列腺癌患者中收集数据。
我们的研究估计前列腺癌的经济负担为 744990 美元。直接医疗成本占 63.50%，总计 153330 美元，其中治疗是最大的组成部分。直接非医疗成本为 62130 美元，生产力损失导致的间接成本为 209760 美元。每位患者的计算总成本为 2614.88 美元。根据 2021 年全球疾病负担数据推算，伊朗约有 83000 名前列腺癌患者，全国经济负担估计为 217034040 美元。这一巨大负担凸显了改善保险覆盖范围和早期检测的必要性。研究结果表明，伊朗的政策制定者和医疗保健提供者应制定标准化的成本分析方法，并加强财务保护，以减轻经济负担，改善医疗保健结果和可持续性。
